drug
capecitabine
Marketedupdated 5mo agoby Armas Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- tagApproval72 co-mentions · 36 sources
- tagSmall Molecule36 co-mentions · 36 sources
- tagOncology7 co-mentions · 3 sources
- tagColorectal Cancer2 co-mentions · 2 sources
- companyJapanese Governmental Office1 co-mentions · 1 sources
- companySun Yat-sen Memorial Hospital1 co-mentions · 1 sources
- companyCancer Institute and Hospital Chinese Academy of Medical Sciences1 co-mentions · 1 sources
indications
investigational
Colorectal Cancer
all catalysts(3)
phase 2 completion · 2
Trials studying capecitabine
- phase2ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- phase3Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- phase3A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
- phase2Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- phase3A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
- phase1HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors
- phase1NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
- phase3A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
News(1)
- Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ RhapsidoProcessa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.fiercebiotech · 2mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that